BRNS earnings date and last-quarter result: last quarter beat, P/E -0.47. Updated 2026-07-23.
Barinthus Biotherapeutics (BRNS) Research Hub
Barinthus Biotherapeutics (BRNS) trades on NASDAQ, GB in the Healthcare (Biotechnology) sector. As of 2026-09-08, shares last closed at 0.7401 USD (-2.49%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.47, market cap 0.03B. This hub links to the full technical, earnings and options research available for BRNS.
Last updated 2026-09-08 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, GB |
| Last close | 0.7401 USD (-2.49%) |
| 52-week range | 0.54 USD – 0.8222 USD |
| Trend regime | Range |
| 14-day RSI | 74 (Overbought) |
| Trailing P/E | -0.47 |
| Market cap | 0.03B |
| Dividend yield | 0.00% |
Available research for BRNS
Covered Call on BRNS: how it works, illustrative setup around the real 0.7401 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on BRNS: how it works, illustrative setup around the real 0.7401 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on BRNS: how it works, illustrative setup around the real 0.7401 USD price, max profit/loss, breakeven and when to use it. Educational.
BRNS technical analysis: range, last 0.7401 USD, RSI 74, 52w range 0.54 USD–0.8222 USD, real support/resistance. Updated 2026-09-08.
More on SniperIQ
Frequently asked questions
What sector is BRNS in?
Barinthus Biotherapeutics (BRNS) is classified under Healthcare (Biotechnology), listed on NASDAQ, GB.
Is BRNS in an uptrend or downtrend?
As of 2026-09-08, BRNS is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is BRNS's trailing P/E ratio?
BRNS's trailing P/E is -0.47, with a market cap of 0.03B. See the earnings research page for full valuation detail.